PCRX (Pacira BioSciences) Cyclically Adjusted Book per Share: $15.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCRX Pacira BioSciences Inc PCRX
69 GF Score
Price $24.43
GF Value $29.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted Book per Share?

Pacira BioSciences PCRX -2.36% 69 Cyclically Adjusted Book per Share is $15.03 as of Jun. 2026. GuruFocus rates PCRX with a GF Score™ of 69/100 and a GF Value™ of $29.11 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pacira BioSciences's adjusted book value per share for the three months ended in Jun. 2026 was $16.674. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.03 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Pacira BioSciences was 28.90% per year. The lowest was 14.80% per year. And the median was 22.60% per year.

As of today (2026-08-10), Pacira BioSciences's current stock price is $24.43. Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $15.03. Pacira BioSciences's Cyclically Adjusted PB Ratio of today is 1.63.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 5.52.


Pacira BioSciences  (NAS:PCRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=24.43/15.03
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 5.52.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pacira BioSciences Cyclically Adjusted Book per Share Related Terms


Pacira BioSciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted Book per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.51 9.37 11.25 12.89 14.18

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.67 14.00 14.18 14.66 15.03

PCRX vs ALVO, BIOA, COLL: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PB Ratio falls into.


PCRX
69GF Score
Pacira BioSciences Inc PCRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.674/333.9520*333.9520
=16.674

Current CPI (Jun. 2026) = 333.9520.

Pacira BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 5.731 241.428 7.927
201612 5.842 241.432 8.081
201703 6.762 243.801 9.262
201706 6.475 244.955 8.827
201709 6.528 246.819 8.833
201712 6.872 246.524 9.309
201803 6.840 249.554 9.153
201806 7.093 251.989 9.400
201809 7.337 252.439 9.706
201812 7.792 251.233 10.358
201903 7.932 254.202 10.420
201906 8.212 256.143 10.707
201909 8.301 256.759 10.797
201912 8.470 256.974 11.007
202003 8.881 258.115 11.490
202006 9.110 257.797 11.801
202009 13.499 260.280 17.320
202012 14.201 260.474 18.207
202103 14.805 264.877 18.666
202106 15.464 271.696 19.007
202109 16.140 274.310 19.649
202112 16.328 278.802 19.558
202203 15.746 287.504 18.290
202206 16.520 296.311 18.619
202209 16.791 296.808 18.892
202212 16.874 296.797 18.986
202303 16.707 301.836 18.485
202306 17.410 305.109 19.056
202309 17.911 307.789 19.433
202312 18.720 306.746 20.380
202403 19.179 312.332 20.507
202406 19.066 314.175 20.266
202409 16.243 315.301 17.204
202412 16.832 315.605 17.810
202503 17.253 319.799 18.017
202506 16.878 322.561 17.474
202509 16.925 324.800 17.402
202512 16.857 324.054 17.372
202603 16.634 330.213 16.822
202606 16.674 333.952 16.674

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $15.03 mean?
Pacira BioSciences (PCRX) has a Cyclically Adjusted Book per Share of $15.03 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted Book per Share too high?
Pacira BioSciences' current Cyclically Adjusted Book per Share is $15.03. Overall, Pacira BioSciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted Book per Share compare to ALVO and BIOA?
Pacira BioSciences' Cyclically Adjusted Book per Share of $15.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted Book per Share is $15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.11, compared to a current price of $24.43 — trading 16.1% below its estimated fair value. The current Cyclically Adjusted Book per Share is $15.03. Pacira BioSciences' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Cyclically Adjusted Book per Share is $15.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (PCRX) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of $24.43 is trading 16.1% below its estimated GF Value™ of $29.11. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for PCRX:

  • Cyclically Adjusted Book per Share: $15.03
  • GF Value™: $29.11 vs. price of $24.43 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges 82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
69GF Score

Get the complete analysis for PCRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.43
Price
$29.11
GF Value